Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric age group. Less than 500 new cases are seen each year in the United States, however. Because of this relatively low incidence, Phase III treatment strategies and various clinical-pathological characteristics of this malignancy are studied most effectively through a collaborative intergroup mechanism. In 1972, the multidisciplinary Intergroup Rhabdomyosarcoma Study (IRS) was initiated by Cancer and Leukemia Group B (CALGB), Children’s Cancer Study Group (CCSG) and the Southwest Oncology Group (SWOG). The IRS has completed two studies (1972–78; 1978–84) and is in midst of the third (1984-present). The current participating cooperative groups are CCSG, the Pediatric Oncology Group (formerly the pediatric divisions of CALGB and SWOG) and, since 1980, the United Kingdom Children’s Cancer Study Group.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Maurer HM, Beltangady M, Gehan EA, et al.: The Inter-group Rhabdomyosarcoma Study-I: A final report. Cancer (in press).
Maurer HM, Foulkes M, Gehan E (for the IRS Committee of CCSG and POG): Intergroup Rhabdomyosarcoma Study-II (IRS-II): A preliminary report. Proc Am Soc Clin Oncol 2:70, 1983.
Maurer HM, Raney RB, Rogab A, et al.: Improved survival of children with group III rhabdomyosarcoma (non-special pelvic sites): A report of IRS-II. Proc Am Soc Clin Oncol 5:202, 1986.
Rodary C, Rey A, Rezvani A, et al.: Prognostic factors in children with rhabdomyosarcoma. Proc XVII Intl Soc Pediatr Oncol, Venice, Italy, p.98, 1985.
Flamant F, Hill C: The improvement in survival associated with combined chemotherapy in childhood rhabdomyosarcoma. Cancer 53:2417, 1984.
Otten J, Flamant F, Rodary C, et al.: Effectiveness of combination of ifosfamide, vincristine and actinomycin D in inducing remission in rhabdomyosarcoma in children. Proc Am Soc Clin Oncol 4:236, 1985.
Carli M, Perilongo G, Guglielmi M, et al.: Rhabdomyosarcoma in childhood: A report from the Italian Cooperative Group. Proc XVII Intl Soc Pediatr Oncol, Venice, Italy, p.89, 1985.
Etcubanas E, Horowitz M, Vogel R: Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 69:999, 1985.
Miser J, Kinsella T, Triche T, et al.: Treatment of high-risk sarcomas with an intensive consolidation followed by autologous bone marrow transplantation. Proc Am Soc Clin Oncol 6:218, 1987.
Horowitz M, Etcubanas E, Christensen M, et al.: Melphalan (LPAM), a clinically effective agent for rhabdomyosarcoma as predicted by the xenograft model. Proc Am Soc Clin Oncol 5:206, 1986.
Carli M, Perilongo G, Montezemolo L, et al.: Phase II trials of cis-platin and VP-16 in children with advanced soft tissue sarcoma: A report from the Italian Cooperative Rhabdomyosarcoma Group. Cancer Treat Rep 71:525, 1987.
Maurer HM, Russell EC: Personal communication.
Pratt CB, Horowitz M, Meyer WH, et al.: Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 71:131, 1987.
de Kraker J, Voute PA: Ifosfamide, Mesna and vincristine in paediatric oncology. Cancer Treat Rev 10:165, 1983.
Miser J, Kinsella T, Tsokos, M, et al.: High response rate of recurrent childhood tumors to etoposide (VP-16), Ifosfamide (ifos) and mesna (mes) uroprotection. Proc Am Soc Clin Oncol 5:209, 1986.
Bode U: Methotrexate, a relapse therapy for rhabdomyosarcoma. Am J Pediatr Oncol 8:70, 1986.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Maurer, H.M. (1988). Pediatric Experience in Rhabdomyosarcoma. In: Ryan, J.R., Baker, L.O. (eds) Recent Concepts in Sarcoma Treatment. Developments in Oncology, vol 55. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2691-2_21
Download citation
DOI: https://doi.org/10.1007/978-94-009-2691-2_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7714-9
Online ISBN: 978-94-009-2691-2
eBook Packages: Springer Book Archive